-
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel JF, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV. International Myeloma Working Group Blood 114(9):1729-35. FI: 10.555 (Q1) Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients Paíva B, Vidriales MB, Pérez JJ, Mateo G, Montalbán MA, Mateos MV, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF, GEM (Grupo Español de MM) cooperative study group. PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group Haematologica 94(11):1599-602. FI: 6.416 (Q1) Relapse/Refractory myeloma patient: potential treatment guidelines San Miguel JF. Journal of Clinical Oncology 27(34):5676-7. FI: 17.793 (Q1) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline Richardson P, Sonneveld P, Schuster M, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh J, Boral A, Esseltine D, Wen P, Amato A, Anderson K, San Miguel JF. British Journal of Haematology 144(6):895-903. FI: 4.597 (Q1) Risk stratification in the era of novel therapies San Miguel JF, Mateos MV, Gutierrez NC. Cancer Journal 15(6):457-64. FI: 3.471 (Q2) Solubre and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease Pérez-Andrés M, Almeida J, Martín Ayuso M, De las Heras N, Moro MJ, Martín-Nuñez G, Galende J, Cuello R, Abuín I, Moreno I, Dominguez M, Hernández J, Mateos G, San Miguel JF, Orfao A. International Journal of Cancer 124(2):367-75. FI: 4.722 (Q1) The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients Paíva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de Las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martin A, González Y, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF. Blood 114(20):4369-72. FI: 10.555 (Q1) The research mission in myeloma Richardson PG, San-Miguel JF, Lonial S, Reece D, Jakubowiak A, Hussein M, Jagannath S, Mitsiades CS, Raje N, Kaufman J, Avigan D, Ghobrial I, Schlossman RL, Munshi N, Dalton W, Anderson KC. Leukemia 23(2):422-3. FI: 8.296 (Q1) The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair Maiso P, Colado E, Ocio EM, Garayoa M, Martin J, Atadja P, Pandiella A, San Miguel JF. Leukemia 23(12):2265-74. FI: 8.296 (Q1) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel JF, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P. Annals of Oncology 20(8):1303-17. FI: 5.647 (Q1)
|
